Navigation Links
Elusys' Anthrax Anti-Toxin, Anthim(TM), Enters Second Phase I Clinical Study
Date:4/20/2009

- Anthim Dramatically Improves Survival in Animals with Clinical Symptoms of Anthrax disease -

PINE BROOK, N.J., April 20 /PRNewswire/ -- Elusys Therapeutics, Inc. (Elusys), a privately-held biopharmaceutical company developing antibody-based therapies for the treatment of life-threatening infectious diseases, today announced the initiation of a second Phase I human safety trial of Anthim(TM), a high-affinity humanized and deimmunized monoclonal antibody targeting the anthrax toxin protective antigen.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090420/NY01624LOGO)

The Phase I dose-escalation trial is planned to enroll 45 healthy volunteers and is designed to expand the human safety database. Elizabeth Posillico, Ph.D., President and Chief Executive Officer of Elusys, commented, "We are extremely pleased with the success of our development program for Anthim. Our drug consistently demonstrates remarkable efficacy in treating anthrax infection in animal models and is a strong candidate for addition to the Strategic National Stockpile."

The Company also reported the results of a previously conducted animal efficacy study. A single dose of Anthim provided a significant survival benefit (up to 94 percent survival in treated rabbits vs. 0 percent in controls) when administered to symptomatic rabbits. These results are consistent with several previous rabbit and primate studies that Elusys has conducted and show the dramatic protective effect of Anthim. Dr. Leslie Casey, Vice President of Research, commented, "Anthim has shown significant life-saving potential even when given in a single dose to symptomatic animals many hours after anthrax exposure. In earlier animal studies, Anthim provided 100 percent protection when given within 12 hours of an anthrax exposure. These results have been consistent across studies whether Anthim was used with or without antibiotics. Our first Phase I human safety study demonstrated that Anthim is safe and well-tolerated as a monotherapy and as a combined therapy with the antibiotic ciprofloxacin. This second study will continue to expand our safety database and provide additional pharmacokinetic data."

Dr. Posillico added, "Death from the effects of anthrax toxin can occur in a few days if patients are not treated quickly. We are very excited about Anthim because the results of all of our studies show that treatment with Anthim has the potential to provide significant therapeutic benefit for people infected with anthrax in a bioterrorism emergency." Currently antibiotics represent the only therapeutic option for anthrax infection. Antibiotics target the bacteria, but can still fail to prevent death from the damaging effects of anthrax toxins. In addition, antibiotic resistant strains of anthrax could be used in a bioterror attack, making the medical need for anti-toxin therapy even more acute.

Anthim Background

Anthim is a high-affinity, humanized and deimmunized monoclonal antibody that targets the protective antigen of B. anthracis and neutralizes the lethal effects of anthrax toxins. It is being developed for prevention and treatment of inhalation anthrax. Anthim has been granted Fast-Track status and Orphan Drug Designation by the FDA. The National Institutes of Health and the Department of Defense have awarded Elusys a total of $34 million for the development of Anthim, of which $12 million was awarded in September 2007 under contract #HHSN272200700035 from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and the Biomedical Advanced Research and Development Authority (BARDA), part of the Department of Health and Human Services. In April of 2007, Anthim was selected to R&D Directions' list of "100 Great Investigational Drugs."

About Elusys

Elusys, a private company based in Pine Brook, New Jersey, is focused on the development of antibody therapeutics for the treatment of life-threatening disease. Current venture investors include Essex Woodlands Health Ventures LLC, Invesco Private Capital, Crescendo Ventures, MedImmune Ventures and Pfizer. For more information please visit www.elusys.com.

    Contact:  Debra Duffy
              973 808 0222 x212
              dduffy@elusys.com


'/>"/>
SOURCE Elusys Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Niaid / Barda Awards Elusys a $12 Million Contract to Further Develop Anthim, the Companys Anthrax Therapeutic
2. Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile
3. New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies
4. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
5. Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM)
6. Another LNA-based RNA Inhibitor Enters Clinical Trials
7. Sanofi Pasteur Dengue Vaccine Enters Pediatric Efficacy Clinical Study
8. ESBATechs Antibody Fragment Enters Phase Ib/IIa in Ophthalmology
9. ESBATechs Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity
10. ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers
11. PreMD Inc. Enters Clinical Study with Cosmetics Conglomerate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... , May 25, 2017  In response to ... , Direct Relief is working with Pfizer to ... available at no cost to community health centers, free ... providers nationwide. "Pfizer has a long-standing ... medicines and ensuring patient safety through educational activities," said ...
(Date:5/22/2017)... , May 22, 2017  Lilac Corp, ... Gene-Eden-VIR/Novirin, announces the launch of a new ... the results of a clinical study that showed ... treatment with Gene-Eden-VIR/Novirin in individuals suffering from HPV ... note that there are no other treatments that ...
(Date:5/18/2017)... N.J. , May 17, 2017  Bayer announced ... oncology portfolio will be presented at the 53 rd ... Oncology (ASCO), taking place June 2-6 in ... presented at ASCO span prostate, colorectal, liver and thyroid ... analysis from the Phase II CHRONOS-1 trial of copanlisib ...
Breaking Medicine Technology:
(Date:5/28/2017)... ... May 28, 2017 , ... Starting in May, patients at The Bay ... Variability (HRV) diagnostic test. , Nerve-Express, originally designed for the Navy in the 1980s, ... of a patient’s autonomic nervous system (ANS). The ANS controls all the critical ...
(Date:5/27/2017)... Los Angeles, California (PRWEB) , ... May 26, 2017 , ... ... Canadian senior citizens who visit a doctor for colds or respiratory issues that are ... note that excessive time pressure on doctors may be largely responsible for the problem ...
(Date:5/26/2017)... NY (PRWEB) , ... May 26, 2017 , ... Mediaplanet ... & Wound Care" campaign in USA Today, which will educate readers on how to ... of the campaign, a large focus is placed on melanoma. Dancing with the Stars ...
(Date:5/26/2017)... ... May 26, 2017 , ... Somnoware, a leading provider ... monitor with its Somnoware Sleep Device Interface (SDI). Somnoware SDI is a sleep ... With this platform, initializing devices and importing studies are just one-click operations. This ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... After raising ... Antzy Top gadget will continue to be available at a discounted crowdfunding price on ... with stress wherever they are, I also wanted to bring a fidget toy to ...
Breaking Medicine News(10 mins):